Peter Verheesen

Peter Verheesen

Company: ArgenX

Job title: Research Fellow


FcRn Inhibition As A Novel Approach For Treating Autoimmune Blistering Disorders 10:30 am

Investigating Efgartigimod as a human IgG1 Fc fragment which outcompetes endogenous IgG from binding to FcRn thereby decreasing its half-life and circulating concentration. Relaying a recent phase 2 study in patients with mild to moderate pemphigus, an autoimmune blistering disorder, where efgartigimod has demonstrated an early onset of disease control allowing for early corticosteroid tapering…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.